Blog
RSS FeedPosted by Michael Wonder on 20 Nov 2019
Medexus granted priority review status for Gliolan by Health Canada
19 November 2019 - Medexus Pharmaceuticals today announced that Health Canada has granted priority review status for the new drug ...
Posted by Michael Wonder on 15 Nov 2019
Valeo Pharma announces filing of a new drug submission for low molecular weight heparin in Canada
14 November 2019 - Valeo Pharma announced today that the new drug submission filed for a low molecular weight heparin ...
Posted by Michael Wonder on 13 Nov 2019
Exelixis’ partner Ipsen announces Health Canada’s approval of Cabometyx (cabozantinib) tablets for the treatment of patients with previously treated advanced hepatocellular carcinoma
12 November 2019 - Approval based on statistically significant and clinically meaningful overall survival benefit demonstrated in the CELESTIAL phase 3 ...
Posted by Michael Wonder on 09 Nov 2019
Xeomin Cosmetic licensed for additional indications In Canada
7 November 2019 - Merz Pharma has announced that Health Canada has provided marketing authorization for additional indications for Xeomin ...
Posted by Michael Wonder on 09 Nov 2019
Janssen announces Health Canada approval of Imbruvica (ibrutinib) in combination with obinutuzumab for treatment naïve patients with chronic lymphocytic leukaemia
8 November 2019 - Patients experienced a 77% reduction in risk of disease progression or death compared to chlorambucil plus obinutuzumab. ...
Posted by Michael Wonder on 07 Nov 2019
Endoceutics receives Health Canada approval for Intrarosa
6 November 2019 - The first innovative drug for the treatment of vulvovaginal atrophy with prasterone. ...
Posted by Michael Wonder on 31 Oct 2019
Janssen announces Health Canada approval of Darzalex (daratumumab) in combination with lenalidomide and dexamethasone for newly diagnosed patients with multiple myeloma who are transplant ineligible
30 October 2019 - This Darzalex combination regimen reduced the risk of disease progression or death by 44% in newly ...
Posted by Michael Wonder on 24 Oct 2019
Knight Therapeutics and SIFI announce approval of Netildex in Canada
23 October 2019 - Knight Therapeutics and SIFI today announced that Health Canada has approved Netildex for the treatment of inflammatory ...
Posted by Michael Wonder on 21 Oct 2019
Bausch Health announces updated Health Canada safety information for Elidel
17 October 2019 - Topical atopic dermatitis treatment Elidel now available for children three months and over. ...
Posted by Michael Wonder on 19 Oct 2019
Cipher Pharmaceuticals receives Health Canada approval for Trulance (plecanatide)
18 October 2019 - Cipher Pharmaceuticals today announced it has received Health Canada approval, on 10 October 2019, for Trulance (plecanatide), ...
Posted by Michael Wonder on 16 Oct 2019
Health Canada approves Ipsen's Cabometyx (cabozantinib) for the first-line treatment of adults with advanced renal cell carcinoma
15 October 2019 - Cabometyx demonstrated a statistically significant, 52% reduction in the risk of progression or death compared with sunitinib, ...
Posted by Michael Wonder on 12 Oct 2019
Canada's decision to make public more clinical trial data puts pressure on FDA
11 October 2019 - Last March, Canada's department of health changed the way it handles the huge amount of data ...
Posted by Michael Wonder on 10 Oct 2019
Two new options for self-administration of Nucala now approved in Canada, making it the first anti-IL5 biologic to offer patients with severe eosinophilic asthma a choice of how and where to receive treatment
9 October 2019 - Nucala (mepolizumab) has been approved in Canada in two new formats – a pre-filled auto-injector and ...
Posted by Michael Wonder on 09 Oct 2019
Health Canada approves Evenity for the treatment of osteoporosis in post-menopausal women at high risk for fracture
8 October 2019 - Today Amgen Canada announced that Evenity (romosozumab) is now available in Canada for the treatment of osteoporosis ...
Posted by Michael Wonder on 09 Oct 2019
Health Canada approves Calquence (acalabrutinib) for adult patients with previously-treated mantle cell lymphoma
8 October 2019 - Approval of the highly selective Bruton's tyrosine kinase inhibitor in mantle cell lymphoma marks AstraZeneca's entry ...